Barbara Van Der Pol1, Edith Torres-Chavolla2, Salma Kodsi2, Charles K Cooper2, Thomas E Davis3, Kenneth H Fife4, Stephanie N Taylor5, Michael H Augenbraun6, Charlotte A Gaydos7. 1. From the Division of Infectious Diseases, University of Alabama at Birmingham School of Medicine, Birmingham, AL. 2. Becton, Dickinson and Company, BD Life Sciences-Diagnostic Systems, Sparks, MD. 3. Sidney and Lois Eskenazi Hospital. 4. Indiana University School of Medicine, Indianapolis, IN. 5. School of Medicine, Louisiana State University Health Sciences Center, New Orleans, LA. 6. Division of Infectious Diseases, SUNY Downstate College of Medicine, Brooklyn, NY. 7. Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, MD.
Abstract
BACKGROUND: Diagnostic options to combat the increasing rates of sexually transmitted infections recorded throughout the world increasingly include multiplex assays. Here we describe the estimated sensitivity and specificity of a triplex molecular assay that simultaneously detects Chlamydia trachomatis (CT), Neisseria gonorrhoeae (or gonococci [GC]), and Trichomonas vaginalis (TV). METHODS: Participants (2547 women and 1159 men) were recruited from 12 clinics in the United States. BD CTGCTV2 for BD MAX System assay (CTGCTV2) results were obtained from vaginal and endocervical swabs, endocervical samples in cytology medium, and female and male urine. Results were compared with infection standards that were sample type and pathogen dependent. RESULTS: Female specimen sensitivity estimates ranged from 92.7% to 98.4%, 92.9% to 100%, and 86.6% to 100% for CT, GC and TV, respectively. Male urine sensitivity estimates were 96.7%, 99.2%, and 97.9% for CT, GC, and TV, respectively. Specificity estimates were >98.7% for all sample types. CONCLUSIONS: BD CTGCTV2 performed well using a variety of sample types. As a true triplex assay, performed using a benchtop instrument, BD CTGCTV2 may be useful in settings where no testing is currently performed and in settings, such as reference laboratories, where testing turnaround time may be several days. Use of this assay at local laboratories may result in greater access to testing and a shorter time to result, which are important steps for improving our ability to combat sexually transmitted infections.
BACKGROUND: Diagnostic options to combat the increasing rates of sexually transmitted infections recorded throughout the world increasingly include multiplex assays. Here we describe the estimated sensitivity and specificity of a triplex molecular assay that simultaneously detects Chlamydia trachomatis (CT), Neisseria gonorrhoeae (or gonococci [GC]), and Trichomonas vaginalis (TV). METHODS: Participants (2547 women and 1159 men) were recruited from 12 clinics in the United States. BD CTGCTV2 for BD MAX System assay (CTGCTV2) results were obtained from vaginal and endocervical swabs, endocervical samples in cytology medium, and female and male urine. Results were compared with infection standards that were sample type and pathogen dependent. RESULTS: Female specimen sensitivity estimates ranged from 92.7% to 98.4%, 92.9% to 100%, and 86.6% to 100% for CT, GC and TV, respectively. Male urine sensitivity estimates were 96.7%, 99.2%, and 97.9% for CT, GC, and TV, respectively. Specificity estimates were >98.7% for all sample types. CONCLUSIONS: BD CTGCTV2 performed well using a variety of sample types. As a true triplex assay, performed using a benchtop instrument, BD CTGCTV2 may be useful in settings where no testing is currently performed and in settings, such as reference laboratories, where testing turnaround time may be several days. Use of this assay at local laboratories may result in greater access to testing and a shorter time to result, which are important steps for improving our ability to combat sexually transmitted infections.
Authors: Arlene C Seña; William C Miller; Marcia M Hobbs; Jane R Schwebke; Peter A Leone; Heidi Swygard; Julius Atashili; Myron S Cohen Journal: Clin Infect Dis Date: 2006-11-27 Impact factor: 9.079
Authors: Sabrina S Plitt; Richard S Garfein; Charlotte A Gaydos; Steffanie A Strathdee; Susan G Sherman; Taha E Taha Journal: Sex Transm Dis Date: 2005-07 Impact factor: 2.830
Authors: Julius Schachter; Max A Chernesky; Dean E Willis; Paul M Fine; David H Martin; Deanna Fuller; Jeanne A Jordan; William Janda; Edward W Hook Journal: Sex Transm Dis Date: 2005-12 Impact factor: 2.830
Authors: Barbara Van Der Pol; Stephanie N Taylor; Oliver Liesenfeld; James A Williams; Edward W Hook Journal: Sex Transm Dis Date: 2013-03 Impact factor: 2.830